Home » Topics » Disease categories and therapies » Urology

Urology
RSS

Potent, orally active AVP receptor antagonist increases urine output in rats

July 14, 1999

KRP-197: new bladder-selective antimuscarinic agent in clinical trials for bladder dysfunction

July 14, 1999

Two more European countries permit phase II studies of resiniferatoxin

July 8, 1999

Uroselective alpha-adrenoceptor blocker GYKI-16084 assessed in BPH and spinal cord injury models

July 7, 1999

Angiotensin II blockade as a strategy for preventing renal allograft nephropathy

July 2, 1999

Nippon Kayaku's new agents for micturition disorders

July 1, 1999

Shire reports positive phase II results for Lambda

June 30, 1999

FDA approves 15-mg Ditropan XL tablets

June 30, 1999

Zeria designs dual-action arylpiperazines for BPH

June 28, 1999

WAY-133537: safe and effective agent for bladder instability

June 28, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...